en · de · es
aod-9604-notes.peptides4962.com › Data › Background And Development History — Background and Details

Background And Development History — Background and Details

By Editorial Desk · published 2026-07-31 · last reviewed 2026-08-01 · Data

AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Development History

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Mechanism And Metabolic Effects

Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.

A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from C-terminal region of human growth hormone
Approximate molecular massAbout 1.8 kDaVaries with sequence length and counterions
Confirmed receptor targetNone establishedNo confirmed growth hormone receptor agonism
Reported in vitro activityLipolysis stimulation and lipogenesis inhibitionObserved mainly in adipocyte models; human relevance uncertain
Regulatory statusNot approved as a drug in major marketsMay be treated differently across jurisdictions; not a recognized dietary ingredient in some countries

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

Related pages on this site

Research and Regulatory Status

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Supporting material

Classical contact mechanics is most notably associated with Heinrich Hertz. In 1882, Hertz solved the contact problem of two elastic bodies with curved surfaces. This still-relevant classical solution provides a foundation for modern problems in contact mechanics. For example, in mechanical engineering and tribology, Hertzian contact stress is a description of the stress within mating parts. The Hertzian contact stress usually refers to the stress close to the area of contact between two spheres of different radii. It was not until nearly one hundred years later that Kenneth L. Johnson, Kevin Kendall, and Alan D. Roberts found a similar solution for the case of adhesive contact. This theory was rejected by Boris Derjaguin and co-workers who proposed a different theory of adhesion in the 1970s. The Derjaguin model came to be known as the Derjaguin–Muller–Toporov (DMT) model (after Derjaguin, M. V. Muller and Yu. P. Toporov), and the Johnson et al. model came to be known as the Johnson–Kendall–Roberts (JKR) model for adhesive elastic contact. This rejection proved to be instrumental in the development of the David Tabor and later Daniel Maugis parameters that quantify which contact model (of the JKR and DMT models) represent adhesive contact better for specific materials. Further advancement in the field of contact mechanics in the mid-twentieth century may be attributed to names such as Frank Philip Bowden and Tabor. Bowden and Tabor were the first to emphasize the importance of surface roughness for bodies in contact.

Canada is recognized as a middle power for its role in global affairs with a tendency to pursue multilateral and international solutions. The country actively promotes its domestically shared values of human rights, the rule of law and foreign aid through membership in multiple international organizations. The "golden age of Canadian diplomacy" refers to a period in Canadian history, typically considered to be the mid-twentieth century, when Canada experienced a high level of success in its foreign relations and diplomatic efforts. Canada's leading role in the creation of the Universal Declaration of Human Rights and its development of modern peacekeeping during this period played a major role in the country's positive global image. The country has since fostered a favourable reputation on the world stage, widely viewed as a responsible and ethical country. Canada and the United States have a long and complex relationship; historically close allies, they have co-operated regularly on military campaigns and humanitarian efforts. Canada also maintains traditional ties to the United Kingdom and to France, along with both countries' former colonies, through its membership in the Commonwealth of Nations and the Organisation internationale de la Francophonie. Canada is noted for having a positive relationship with the Netherlands, owing, in part, to its contribution to the Dutch liberation during the Second World War. Canada has diplomatic and consular offices in over 270 locations in approximately 180 foreign countries.

The cells of fungi have in addition to the shared eukaryotic organelles a spitzenkörper in their endomembrane system, associated with hyphal tip growth. It is a phase-dark body that is composed of an aggregation of membrane-bound vesicles containing cell wall components, serving as a point of assemblage and release of such components intermediate between the Golgi and the cell membrane. The spitzenkörper is motile and generates new hyphal tip growth as it moves forward. The cell walls of fungi are uniquely made of a chitin-glucan complex. Chloroplasts are not found in fungal cells, their pigments are instead associated with their cell walls.

Traditionally used packaging films like LDPE (low-density polyethylene), PVC (polyvinyl chloride), EVA (ethylene-vinyl acetate) and OPP (oriented polypropylene) are not permeable enough for highly respiring products like fresh-cut produce, mushrooms and broccoli. As fruits and vegetables are respiring products, there is a need to transmit gases through the film. Films designed with these properties are called permeable films. Other films, called barrier films, are designed to prevent the exchange of gases and are mainly used with non-respiring products like meat and fish. MAP films developed to control the humidity level as well as the gas composition in the sealed package are beneficial for the prolonged storage of fresh fruits, vegetables and herbs that are sensitive to moisture. These films are commonly referred to as modified atmosphere/modified humidity packaging (MA/MH) films.

Sources: en.wikipedia.org

Notes from published material

=== Treatment by medical professionals === In a healthcare setting, treatment depends on the severity of symptoms and intravenous access. If a patient is conscious and able to swallow safely, food or drink may be administered, as well as glucose tabs or gel. In those with intravenous access, 25 grams of 50% dextrose is commonly administered. When there is no intravenous access, intramuscular or intra-nasal glucagon may be administered.

... consciously and unconsciously reflected a number of deep American anxieties that grew out of more than two decades of the Cold War. By the mid–1960s, some Americans began to critique what they saw as mindless nationalism. This unthinking patriotism had coalesced as part of a liberal consensus grounded in confidence in the essential soundness of American society as well as the assumption of a pervasive communist threat to the U.S. and its allies. Many supporters of the liberal consensus believed that economic growth and development would solve any remaining social inequalities while damping class conflict. Like Bernardi, Austin discusses racial stereotypes in the episode. Citing Bernardi, he argues that, instead of considering "the Yangs as noble savages, the Yangs can now be seen as an example of the result of mindless nationalism run amok, albeit still salvageable in Roddenberry's ever-optimistic view of the future." He adds, "Many of the qualities ascribed to the Yangs mirrored terms used to describe the 'yellow peril' at an earlier time in U.S. history. For example, Tracy, after noting directly that the Yangs are white, describes them as vicious and deceptive enemies who cannot communicate intelligently." In "The Omega Glory", a 2006 essay reflecting on stories that have tried to imagine the future, Michael Chabon says, "Eed plebnista, intoned the devolved Yankees, in the Star Trek episode 'The Omega Glory', who had somehow managed to hold on to and venerate as sacred gobbledygook the Preamble to the Constitution, norkon forden perfectunun.

=== Opioid addiction === In his Deposition: Testimony Concerning a Sickness in the introduction to later editions of Naked Lunch (first published in 1959), William S. Burroughs wrote that apomorphine treatment was the only effective cure to opioid addiction he has encountered:

Sources: en.wikipedia.org

Frequently asked questions

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Is AOD9604 approved as a medicine?

It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.

Does AOD9604 raise IGF-1 levels?

In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.

How is AOD-9604 thought to work?

It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.

Network